Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
NPJ Precision Oncology|January 28, 2022
Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapyI Lodewijk, A Bernardini, C Suárez-Cabrera, et al.
Breast Cancer Research and Treatment|May 19, 2015
Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE studyMiguel J Gil-Gil, M Bellet, S Morales, et al.
ESMO Open|July 30, 2021
Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)J A Perez-Fidalgo, A Cortés, E Guerra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2009
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial)E M Ciruelos, J Cortés, H Cortés-Funes, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 15, 2014
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancerJ Salvador, L Manso, J de la Haba, et al.
Current Oncology (Toronto, Ont.)|April 25, 2015
Use of bevacizumab as a first-line treatment for metastatic breast cancerL Manso, F Moreno, R Márquez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockadeP Nuciforo, T Pascual, J Cortés, et al.
NPJ Precision Oncology|March 20, 2021
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancerG Griguolo, G Serna, T Pascual, et al.
Nature Communications|December 8, 2022
Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin AS Mouron, M J Bueno, A Lluch, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 14, 2019
Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experienceS Pérez Ramírez, M Del Monte-Millán, S López-Tarruella, et al.
Pageof 3